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Nuclear hormone receptors, including RXR and PPARγ, represent novel therapeutic targets in melanoma. We have previously
shown that the DRO subline of the amelanotic melanoma A375 responds to rexinoid and thiazolidinedione (TZD) treatment
in vitro and in vivo. We performed microarray analysis of A375(DRO) after TZD and combination rexinoid/TZD treatment in
which the calcium binding protein S100A2 had increased expression after rexinoid or TZD treatment and a synergistic increase
to combination treatment. Increased S100A2 expression is dependent on an intact PPARγ receptor, but it is not suﬃcient to
mediate the antiproliferative eﬀects of rexinoid/TZD treatment. Over expression of S100A2 enhanced the eﬀect of rexinoid and
TZD treatment while inhibition of S100A2 expression attenuated the response to rexinoid/TZD treatment, suggesting that S100A2
is necessary for optimal response to RXR and PPARγ activation by respective ligands. In summary, we have identiﬁed potential
downstream mediators of rexinoid and TZD treatment in a poorly diﬀerentiated melanoma and found that alterations in S100A2
expressionaﬀectRXRandPPARγ signalinginA375(DRO)cells.Thesestudiesprovideinsightintopotentialmechanismsoftumor
response or resistance to these novel therapies.
1.Introduction
Melanoma represents a signiﬁcant public health problem
with a rising incidence over the last 3 decades [1]. More
than 7700 patients will die of this disease annually, almost
a l lw i t hm e t a s t a s e s[ 2]. The median survival in patients with
metastatic disease is 7–9 months [3] .W h i l es o m ep r o g n o s t i c
factors correlate with a more favorable prognosis, such as
lack of visceral metastases, younger age, and treatment with
biochemotherapy, the 5–10-year survival rates still remain
less than 20% [4]. Thus, a search for novel therapies is
warranted in this aggressive disease given the suboptimal
choices available.
We have reported the eﬃcacy of rexinoid, thiazolidine-
dione, and combination therapy in the melanoma cell line
A375(DRO)(DROwasoriginallythoughttobeananaplastic
thyroid cancer cell line) [5–7]. Additionally, we have shown
that RXR and PPARγ receptors are necessary for optimal
response to rexinoid or TZD therapies, as knock down of
either receptor attenuates the antiproliferative response to its
ownligandaloneortheligandofitsheterodimerpartner[8].
In this report, we explore potential downstream medi-
ators of the rexinoid and TZD treatment eﬀect in the
A375(DRO) melanoma cancer cell line using comparative
gene expression microarray analysis. We have identiﬁed the
calcium binding protein S100A2 as a potential mediator of
rexinoid and TZD signaling in melanoma. S100A2 is one of
24 members of S100 proteins that regulate cellular processes
including neoplasia and has signiﬁcantly increased gene
expression in A375(DRO) with rexinoid and TZD, while a
synergistic eﬀect is seen with combination therapy [9].
2.MaterialsandMethods
2.1. Cell Line and Chemicals. A375(DRO) was provided by
Dr. G.J. Juillard (University of California at Los Angeles, Los2 PPAR Research
Angeles, CA). DRO was previously thought to be derived
from an anaplastic thyroid cancer. We have shown that it
is genetically identical to the melanoma cell line A375 and
is therefore designated as a subline of A375, A375(DRO)
[7, 8]. A375(DRO) was grown in RPMI 1640 (Invitrogen
Corporation) supplemented with 2% fetal bovine serum
(Hyclone) and 0.5% penicillin/streptomycin. LGD1069 was
provided by Ligand Pharmaceuticals (San Diego, CA), and
Rosiglitazone (ROSI) was provided by GlaxoSmithKline.
2.2. Microarray Analysis. Four million A375(DRO) cells
were plated in triplicate into 100mm plates and incu-
bated overnight. The next day, the medium was changed,
and medium with volume equivalent vehicle (DMSO) or
1μmol/L of LGD1069, ROSI, or the combination (500nM of
each) was added in the set of cells to incubate for 24 hours.
RNA was extracted from treated cells using the QIAGEN
RNeasyMiniKitandwasquantiﬁedbystandardspectropho-
tometry. RNA integrity was veriﬁed by gel electrophoresis
using an Agilent 2100 Bioanalyzer. Total RNA (5μg) was
converted to ds-cDNA using the Superscript Choice System
(LifeTechnologies).Ahigh-pressureliquidchromatography-
puriﬁed T7-(dT)24 primer was used to initiate the cDNA
reverse transcription. After the synthesis of both strands of
DNA, the ds-cDNA was extracted with phenol-chloroform-
isoamylalcoholandrecoveredbyethanolprecipitation.Next,
in vitro transcription of cRNA was done and the transcript
underwent biotin labeling using an RNA Transcript Labeling
Kit (Enzo). Biotin-labeled cRNA was puriﬁed using the
QIAGENRNeasyMiniKit.TheRNAwasthenfragmentedby
incubatingthecRNAat94◦Cfor35minutestoallowoptimal
hybridization to the cDNA oligonucleotide array. We used
the Aﬀymetrix GeneChip Human Genome U133A platform,
and all gene chip processing and analyses occurred in the
UCHSC Aﬀymetrix microarray core facility. Each condition
was run in triplicate from three independent experiments.
Data analysis, including background adjustment and nor-
malization, was done using Aﬀymetrix GeneSpring software.
For microarray analysis, those genes that had at least a >2-
fold change in more than three of six gene chips between
ligand and vehicle treatment of DRO cells were selected
as signiﬁcant. Signiﬁcance was determined by a one-way
ANOVA (P<. 05).
2.3. Quantitative Reverse Transcription-PCR (qRT-PCR).
Total RNA was isolated from A375(DRO) in single sam-
ples under the same conditions used for the microarray
experiment using the RNeasy Mini Kit (Quiagen, Valencia,
CA) as per the manufacturer’s protocol. The mRNA for
S100A2 was measured by real-time Quantitative RT-PCR
using ABI PRISM 7700. The sequences of forward and
reverse primers as designed by Primer Express (PE ABI)
were 5 -TTCCTGGGTCTGTCTCTGCC-3  and 5 -AGC-
GCCTGCTCCAGAGAAC-3 .
The TaqMan ﬂuorogenic probe used was 6FAM-TGG-
TCTGCCACAGATCCATGATGTGC-TAMRA.
Ampliﬁcation reactions, thermal cycling conditions, and
generation of a standard curve have been described previ-
ously [6].
2.4. S100A2 Overexpression. Human S100A2 in pcDNA3
vector was the generous gift from Professor C. Heizmann
(University of Zurich). A375(DRO) cells were stably trans-
fected with S100A2 in pcDNA3 vector and empty vector
using lipofectamine method in 6-well cell culture plates
(4μg/well) as previously described [10]. Thereafter stable
clones were selected and continuously cultured in 150μg/mL
G418(Gibco/BRL).
2.5. shRNA. We used a lentiviral mediated shRNA system
from Sigma (St. Louis, MO) and followed the manufac-
turer’s protocol. Lentiviral particles contain shRNA toward
S100A2 or PPARγ or RXRγ-speciﬁc sequences as well as
a scrambled (SCR) sequence that consists of 5 nucleotides
that do not match any known gene transcript in both the
murine and human genome. The infected cells are selected
by a puromycin resistance and then assessed for correct
insertion/RNA inhibition by qRT-PCR or western blot for
S100A2, PPARγ,o rR X R γ. The concentration of puromycin
used to select for DNA construct incorporation cells was
0.4μg/mL.
2.6. Western Blot Analysis. Whole cell protein extracts were
obtained from A375(DRO) under conditions of volume
equivalent vehicle, LGD1069/ROSI combination treatment,
and with overexpressed S100A2 or shRNA directed at
S100A2. The protein content of lysates was measured using
a commercial protein assay kit (DC from Bio-Rad). Diluted
samples containing equal amounts of protein (60μg) were
mixed with 2x Laemmli sample buﬀer (Bio-Rad Laborato-
ries). Proteins were separated on a 10% SDS-polyacrylamide
gel and transferred to polyvinylidene diﬂuoride membranes.
The membranes were blocked with 1x TBST (20mmol/L
Tris-HCl (pH 7.6), 8.5% NaCl, and 0.1% Tween 20) contain-
ing 5% nonfat dry milk at room temperature for 2 hours
and incubated in the appropriate primary antibody in 1x
TBST containing 5% nonfat dry milk at 4◦C overnight.
S100A2 protein antibodies (Sigma S6797), RXRα (sc 553 and
D-20), RXRβ (sc 831 and C-20), and RXRγ (sc Y-20 and
JC-555) receptor antibodies were used at a concentration
of 1 : 1000, and PPARγ (sc 7196 and H-100) rabbit
polyclonal antibody was used at 1 : 500. After washing,
membranes were incubated for 1 hour at room temperature
with antirabbit IgG conjugated to horseradish peroxidase at
a 1 : 5000 dilution for RXRs and 1 : 1000 for PPARγ (GE
Healthcare UK). β-Actin was probed for loading control.
The enhanced chemiluminescence detection reagent from
Amersham Biosciences was used for immunodetection.
2.7. Cell Growth and Proliferation. A375(DRO) cells at base-
line, with S100A2 overexpressed, with infected SCR shRNA,
and with shS100A2 cells were grown to approximately 80%
conﬂuence in 100mm tissue culture plates. Cells were then
harvested using Trypsin-EDTA (Invitrogen Corporation,
Carlsbad, CA) and counted using a hemocytometer. Cells
were then transferred to a 96-well plate at a concentration
of 500cells/200μL of media. Each row of eight wells received
the same cell type and subsequently the same drug. AfterPPAR Research 3
cells were plated, media with the appropriate concentration
of ligand or equivalent volume of vehicle was added to
each well. Cells were treated with volume equivalent vehicle,
1μMLGD1069,1μMrosiglitazone,orthe1μMcombination
(500nM of each). Fresh media with vehicle or ligand
was added every 72 hours. At the completion of 6 days,
cell proliferation was assessed following the manufacturers
instructionsusingtheCellTiter96AqueousNon-Radioactive
Cell Proliferation Assay (Promega, Madison, WI). Following
a two-hour incubation at 37
◦C, each plate was analyzed by a
MRX Micro plate Reader (Dynatech Laboratories, Chantilly,
VA) using Revelation software.
2.8. Statistics. Cell growth between control and treatment
conditions quantiﬁed using the group mean ± SE and
signiﬁcance was compared between control and treatment
conditions with a Student’s t-test between conditions (SISA
online statistical tool).
3. Results
3.1. Microarray Analysis of LGD1069/ROSI-Treated A375
(DRO) Cells. The antiproliferative eﬀects of rexinoid and
TZDtreatmentonA375(DRO)occuratorbeyondsixdaysof
treatment [5]. However, we chose to analyze gene expression
changes in A375(DRO) at 24 hours since RXRγ and PPARγ
are nuclear hormone receptors, and we would predict direct
geneexpressioneﬀectsoftheseligandedtranscriptionfactors
to occur early. The results of the LGD1069 1μMt r e a t m e n t
arm have been previously published [6]. Microarray analysis
revealed that the combination rexinoid/TZD treatment
resulted in 212 genes with increased expression and 1050
genes with decreased expression (one-way ANOVA P<
.05). These genes broadly fell into the categories of cell
growth, nucleic acid binding, and cell signal transduction.
The 20 genes with the largest change in expression after
treatment are listed in Tables 1, 2, 3,a n d4 (excluding
aﬀymetrix speciﬁc cDNA sequences without related search-
able genes). The complete data set is in the supplementary
materials (see Supplementary Material available online at
doi:10.1155/2010/729876). Four genes were upregulated by
rexinoid/TZD combination therapy greater than 20-fold:
TIE1 (121.5-fold), S100A2 (69.1-fold), ILB-1 (40.1-fold),
and ANGPTL4(32.2-fold) (Table 5 ). Ofthese genes,S100A2
was increased by both the rexinoid (3.4-fold) and TZD
(4.9-fold) but also demonstrated a synergistic stimulation
(69.1-fold) with the combination treatment. In addition, 171
geneshadincreasedexpressionand1006geneshaddecreased
expression by at least 2-fold with ROSI alone (Tables 1, 2,
3,a n d4 —one-way ANOVA P<. 05). Based upon the
signiﬁcant increase of S100A2 mRNA levels with each ligand
alone and the synergistic increase with combination therapy,
we performed additional experiments with S100A2 to deﬁne
itsroleinmediatingtheeﬀectsofcombinationrexinoid/TZD
treatment in melanoma cells. We have previously published
conﬁrmation of ANGPTL4 regulation by rexinoids [6]. The
eﬀects of TZD and rexinoids on TIE-1 and ILB-1 mRNA
and protein expression have not yet been conﬁrmed by other
methods.
Table 1: Microarray Analysis of A375(DRO) cells after TZD/
rexinoid combination treatment—2-fold up regulated genes.
A375(DRO) cells were treated in vitro with 1μmol/L of PIO or
combination LGD1069/PIO for 24 hours compared with volume-
equivalent vehicle in triplicate with a cutoﬀ of a 2-fold change
(P<. 5, one-way ANOVA). Gene symbols were derived from the
Aﬀymetrix web site.
Gene Symbol fold change GenBank ID
TIE1 121.5 NM 005424
S100A2 69.1 NM 005978
IL1B 40.1 NM 000576
ANGPTL4 32.2 NM 001039667
AREG 18.2 NM 001657
RPL37A 12.6 NM 000998
CORO2B 10.9 NM 006091
RPL27A 8.7 NM 000990
INHBA 7.6 NM 002192
ST3GAL1 5.4 NM 003033
TXN 5.0 NM 003329
ITGA3 5.0 NM 002204
FGFR2 5.0 NM 000141
GEM 4.9 NM 005261
COL5A2 4.9 NM 000393
RPL38 4.8 NM 000999
PMEPA1 4.7 NM 020182
MCL1 4.5 NM 021960
RPL38 4.2 NM 000999
SMARCA2 3.8 NM 003070
3.2. An Intact RXRγ and PPARγ Receptor Is Required for
Optimal S100A2 Expression. S100A2 levels were measured
after treatment of A375(DRO) with 1μM combination of
LGD1069andROSI(500nMeach).Todeterminetherelative
contribution of PPARγ and RXRγ, we compared control
cells stably infected with scrambled shRNA with sublines
stably infected with shRNA against PPARγ and RXRγ which
greatlyreducedthelevelsofeachreceptor[8].Figure 1shows
that the rexinoid/TZD-induced expression of S100A2 was
attenuated by lack of either receptor. PPARγ appears to have
the greatest eﬀect on this response.
3.3. S100A2 Overexpression Enhances the Antiproliferative
Response to LGD1069 and ROSI Treatment. S100A2 protein
was overexpressed in A375(DRO) cells, and the empty vector
(EV) was used as a control. Figure 2 shows that the levels
of S100A2 protein in the overexpressing subline (S100A2)
are similar to levels seen after treating A375(DRO) cells
with rexinoid/TZD combination. After plating equivalent
numbers of control (A375(DRO) + EV) and S100A2 over-
expressing cells, we observed no diﬀerence in growth rate at
3a n d6d a y s( Figure 3(a)). However, with 6 days of 1μM
LGD1069, 1μM ROSI, or 1μM combination therapy the
S100A2 overexpressing cells had a signiﬁcant decrease in
proliferation compared to the EV cells relative to vehicle
treatment (64% versus 46% for LGD1069, 86% versus 72%4 PPAR Research
Table 2: Microarray Analysis of A375(DRO) cells after TZD/
rexinoid combination treatment—2-fold down regulated genes.
Gene Symbol fold change GenBank ID
ABAT −17.5N M 000663
TSFM −10.4N M 005726
XRCC4 −9.0N M 003401
NUDT1 −8.9N M 002452
ZIC1 −8.3N M 003412
BARD1 −8.2N M 000465
CDC25A −8.2N M 001789
MAP9 −8.1N M 001039580
QPCT −7.9N M 012413
C12orf52 −7.8N M 032848
PTCD2 −7.3N M 024754
TLE1 −6.8N M 005077
MYO6 −6.4N M 004999
WDR59 −6.0N M 030581
RARS −5.6N M 002887
BIN1 −5.2N M 004305
WBP1 −5.2N M 012477
CSGALNACT1 −5.1N M 018371
CAMTA1 −5.1N M 015215
TRIM23 −5.1N M 001656
Table 3: Microarray Analysis of A375(DRO) cells after TZD/
rexinoid combination treatment—2-fold up regulated with ROSI
alone.
Gene Symbol fold change GenBank ID
ANGPTL4 29.4 NM 001039667
TIE1 13.1 NM 005424
RPL27A 10.9 NM 000990
IL1B 9.3 NM 000576
RPL37A 8.4 NM 000998
AREG 6.1 NM 001657
RPL38 6.1 NM 000999
TACR1 5.6 NM 001058
TXN 5.5 NM 003329
MCL1 5.5 NM 021960
PGK1 5.5 NM 000291
RPL38 5.4 NM 000999
FGFR2 5.2 NM 000141
LOC653505 5.0 NM 001123068
RAB2A 5.0 NM 002865
S100A2 4.9 NM 005978
LOC100131637 4.8 XM 001716033
GBA3 4.7 NM 020973
JUN 4.4 NM 002228
SMARCA2 4.2 NM 003070
Table 4: Microarray Analysis of A375(DRO) cells after TZD/
rexinoid combination treatment—2-fold down regulated with
ROSI alone.
Gene Symbol fold change GenBank ID
ORC4L −15.9N M 002552
TAF12 −8.9N M 005644
ZNF443 −8.1N M 005815
HIGD1A −8.0N M 032775
CYB5R2 −7.9N M 001039580
DAZAP2 −7.5N M 005726
STK32B −7.1N M 024754
ZBTB43 −6.7N M 014007
CAMTA1 −6.6N M 015215
HCG4 −6.4N R 002139
BSCL2 /// HNRNPUL2 −6.3N M 001079559
SLC39A4 −6.0N M 017414
DZIP3 −6.0N M 014648
MSRB2 −6.0N M 018009
KLHL22 −5.8N M 032848
MPP5 −5.7N M 024899
RNF41 −5.6N M 005785
VRK3 −5.5N M 030581
ABAT −5.4N M 000663
BRCA2 −5.3N M 000059
RARS −5.3N M 002887
Table 5: Four genes with the highest mRNA stimulation after
combination TZD/rexinoid treatment.
TIE 1 S100A2 IL1B ANGPTL4
LGD1069/ROSI 121.5 69.1 40.1 32.2
ROSI 13.1 4.9 9.3 29.4
LGD1069∗ <23 . 4<26 . 5
∗data published in [6].
forROSI,and94%versus88%forthecombination;P ≤ .008
for all conditions; Figure 3(b)).
3.4. Knock Down of S100A2 Attenuates the Growth Inhibition
of A375(DRO) Cells by Rexinoid, TZD, and Combination
Treatment. Knock down of S100A2 with speciﬁc shRNA did
not aﬀect growth of A375(DRO) cells (data not shown).
S100A2 shRNA stably expressed in A375(DRO) cells resulted
in a decrease in S100A2 mRNA and protein expression after
treatment with LGD1069/ROSI (Figure 4). Stable expression
of scrambled shRNA (SCR) had no eﬀect. Figure 5 shows
that melanoma cells stably transfected with S100A2 shRNA
had signiﬁcantly blunted growth suppression by treatment
with rexinoid, TZD, or combination (P<. 002 for all
shS100A2 versus SCR treatment conditions). These data
indicate that S100A2 is required to mediate the growth
suppressive eﬀects of TZD and rexinoids in melanoma cells.
Western blot analysis of the cells expressing S100A2 shRNA
revealed decreased levels of RXRγ but RXRα and PPARγ
proteinlevelswereunaﬀected(Figure 6).RXRβproteinlevelsPPAR Research 5
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Figure 1: S100A2 mRNA stimulation by TZD/rexinoid treatment
is dependent on intact PPARγ and RXRγ.O n em i c r o g r a mo ft o t a l
RNA was used for the S100A2 quantitative reverse transcription-
PCR analysis (ABIPRISM7700; Perkin-Elmer), and absolute values
were derived from a standard curve using a known amount of sense
strand RNA (ag, attograms of sense strand RNA). Isoform RNA was
normalized to total input RNA (18s rRNA measured from 1ng of
total RNA). A375(DRO) cells were infected with either shPPARγ or
shRXRγ lenteviral particles and then treated with LGD1069/ROSI
1μM for 24 hours. S100A2 mRNA levels were compared to levels
from A375(DRO) cells infected with the shSCR control under the
same treatment conditions.
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Figure 2: Protein expression of S100A2 in A375(DRO) cells. 60μg
of nuclear protein extract from A375(DRO) before (DMSO—lane
1) and after combination treatment (lane 2) or transfected with
empty vector (EV—lane 3) or S100A2 in pcDNA3 vector with no
treatment (lane 4) was size-separated on a 10% SDS-PAGE gel and
transferred to nitrocellulose. The blot was blocked with 10% nonfat
milk and incubated with S100A2 receptor antibodies (sc Y-20). β-
Actin was measured as a loading control.
are very low in these cells [11]. Analysis of shS100A2 and
RXRγ sequences revealed no sequence homology.
4. Discussion
In this report, we have examined global gene expression
in a poorly diﬀerentiated cancer model, the amelanotic
melanoma cell line A375(DRO), after treatment with PPARγ
and RXR ligands. S100A2 was shown to be a potentially
important target based on increased levels with rexinoid
or TZD treatment and synergistically increased levels with
combination therapy. Furthermore, S100A2 appears to be
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Figure 3: Proliferation of A375(DRO) cells overexpressing S100A2.
Cells were grown in 2% fetal bovine serum RPMI in the presence
of 1μmol/L of LGD1069, TZD, or the combination for 6 days.
Cell growth was analyzed using a nonradioactive cell proliferation
assay. Proliferation was compared directly between EV and S100A2
(a) and then to that of cells grown in volume equivalent vehicle
(set at 100% which represents cell growth in control conditions)
(b). Proliferation was signiﬁcantly decreased in cells with S100A2
overexpression compared to EV for all treatment conditions
compared to control. Columns mean; bars, SEM.
requiredforthemaximalantiproliferativeeﬀectsofrexinoids
and TZD in these melanoma cells.
The S100 proteins have a broad range of intracellular
functions including the regulation of protein phosphoryla-
tion and enzyme activity, calcium homeostasis, regulation
of cytoskeletal proteins, and transcriptional factors [12].
S100 proteins appear to regulate tumorigenesis. For exam-
ple, S100A2 proteins enhance p53 transcriptional activity
whereas S100A4 increases p53 apoptosis in models of
adenocarcinoma, osteosarcoma, and oral carcinoma [12–
14].Thus,arelativeimbalanceofS100proteinsmaypromote
or inhibit neoplastic transformation or progression. S100A2
seems to have a variable pattern of expression with some
evidence pointing to higher expression in normal tissues and6 PPAR Research
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Figure 4: shS100A2 decreases S100A2 mRNA and protein in
A375(DRO) cells. qRT-PCR and Western blot of S100A2. (a)
One microgram of total RNA was used for the S100A2 quantita-
tive reverse transcription-PCR analysis (ABIPRISM7700; Perkin-
Elmer), and absolute values were derived from a standard curve
using a known amount of sense strand RNA (ag, attograms of sense
strand RNA). Isoform RNA was normalized to total input RNA
(18s rRNA measured from 1ng of total RNA). (b) 60μg of nuclear
protein extract from A375(DRO), the SCR shRNA infected control
cell, and shS100A2 infected cells. Proteins were size-separated on a
10% SDS-PAGE gel and transferred to nitrocellulose. The blot was
blocked with 10% nonfat milk and incubated with S100A2 primary
antibody(scY20)andthensecondaryantibodywithantimouseIgG
conjugated to horse-radish peroxidase as previously described. β-
actin was measured as a loading control.
early or premalignant issues, but other types of cancer, such
as lung cancer, have a higher expression in advanced lesions
that correlate with poorer clinical prognosis. However, even
within the lung cancer literature, there is disagreement
regarding the prognostic signiﬁcance of S100A2 expression
[13, 15, 16].
In melanoma, S100 proteins may play a critical role in
regulating the transformation of nevi to melanoma. S100A4
levels are lower in metastatic melanoma compared with
primary tumors, while S100A7, S100A8, and S100A9 levels
appear to be higher in malignant melanoma compared with
normal melanocytes [17]. In a study of 105 patients with
stage IV melanoma, elevated serum levels of S100B were
associated with a signiﬁcantly shorter survival [18].
S100A2 expression is higher in premalignant nevi than
in cells from primary melanoma tumors or metastases
suggesting that loss of S100A2 may be important for
neoplastic transformation [19]. In an in vitro model of
uveal melanoma, S100A2 gene expression was signiﬁcantly
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Figure 5: Knock down of S100A2 blunts the antiproliferative eﬀect
of TZD and rexinoids in A375(DR) cells. A375(DRO), the SCR
infected, and an shS100A2 infected subline were grown in 2%
fetal bovine serum RPMI in the presence of 1μmol/L of LGD1069,
TZD, or the combination for 6 days. Cell growth was analyzed
using a nonradioactive cell proliferation assay. Proliferation was
compared to that of cells grown in volume equivalent vehicle
(DMSO—set at 100%). Proliferation was statistically signiﬁcantly
attenuated compared to the A375(DRO) SCR subline in all
treatment conditions. Columns, mean; bars, SEM.
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Figure 6: Western blot of rexinoid receptors in A375(DRO) cells
after knock down of S100A2. 60μg of nuclear protein extract from
A375(DRO), the SCR shRNA-infected control cell, and a clone of
shS100A2 infected cells were size-separated on a 10% SDS-PAGE
gel and transferred to nitrocellulose. The blot was blocked with
10% nonfat milk and incubated with PPARγ,R X R γ, and RXRα
primary antibodies and then secondary antibody with antirabbit
IgG conjugated to horse-radish peroxidase as previously described.
PARP was measured as a loading control.
up-regulated by the methyltransferase inhibitor decitabine,
which was correlated with cell death [20]. We have demon-
strated that S100A2 levels are low in the A375(DRO)
melanoma cell line, and these levels are increased by treat-
mentwithPPARγ andRXRagonists,whichisassociatedwith
a signiﬁcant reduction in growth and increase in apoptosis
[8].PPAR Research 7
Though other S100 proteins have been shown to increase
with retinoid therapy in models of cancer including tera-
tocarcinoma, breast cancer, and gastric carcinoma [21–23],
this is the ﬁrst report of increased S100A2 expression by
either rexinoids or TZDs. We have previously demonstrated
that, in A375(DRO), the combination of LGD1069 and ROSI
synergistically decreases in vitro cell proliferation and in
vivo tumor growth [5, 8]. Our data indicates that S100A2 is
necessary to mediate the antiproliferative eﬀects of rexinoid
and TZD treatment but is not suﬃcient to mediate this
eﬀect. However, with overexpression of S100A2, we observe
an enhanced eﬀect of rexinoid and TZD treatment on the
melanoma cells.
This observed relative resistance to rexinoid and TZD
treatment with shS100A2 was found in conjunction with
decreased RXRγ protein levels (though the shS100A2
sequence does not overlap with RXRγ). We have previously
shown that decreasing RXRγ by shRXRγ in A375(DRO)
decreases response to rexinoid, TZD, and the combination
[8]. Modulators of retinoid receptors have been described
in melanoma and include HSP 90 and Cyclophilin B [24],
but we were unable to ﬁnd any direct link between S100A2
expression and RXR regulation. It appears as if the presence
of S100A2 is important for optimal RXRγ expression, but
this is most likely not a direct interaction as measurable and
at least partially functional RXRγ (as evidenced by response
to LGD1069) was seen after shS100A2 infection. Further
studies will be needed to elucidate the exact interaction of
S100A2 and retinoid receptors.
I ns u m m a r y ,w eh a v ep e r f o r m e dam i c r o a r r a ya n a l y s i s
of a poorly diﬀerentiated melanoma after rexinoid and
TZD treatment. S100A2 gene expression is signiﬁcantly
increased by both rexinoid and TZD treatment alone and is
synergistically increased by combination therapy. S100A2 is
necessary for the maximal antiproliferative eﬀect of rexinoid
and TZD in this model, but it is not suﬃcient to mediate this
eﬀect.
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